Somatotropin
- Generic Name
- Somatotropin
- Brand Names
- Genotropin, Humatrope, Norditropin, Norditropin Nordiflex, Nutropin, Nutropinaq, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, NutropinAq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12629-01-5
- Unique Ingredient Identifier
- NQX9KB6PCL
- Background
Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotropic cells of the anterior pituitary gland. Growth hormone plays an essential role in growth regulation during childhood as well as other basal metabolic functions, muscle and fat mass regulation, blood glucose level regulation, and li...
- Indication
Somatotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, short stature associated with Turner syndrome, Prader-Willi syndrome (PWS), idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and shor...
- Associated Conditions
- Adult Onset Growth Hormone Deficiency, Cachexia, Childhood-onset Growth Hormone Deficiency, Growth Failure, HIV Wasting Syndrome, Short Bowel Syndrome (SBS), Short Stature
- Associated Therapies
- -
Biosimilars Market Size to Worth USD 114.02 Billion By 2031
The biosimilars market is projected to grow from USD 36.01B in 2024 to USD 114.02B by 2031, at a CAGR of 17.9%. Factors driving growth include rising demand for cost-effective biologics and patent expirations. Key trends include regulatory approvals and new product launches. North America is expected to dominate due to favorable regulations.
Ascendis Pharma's TransCon hGH Scores FDA Filing Acceptance After Superior
Ascendis Pharma announced FDA acceptance of its sBLA for TransCon hGH to treat adult growth hormone deficiency (GHD), with a PDUFA date set for July 27, 2025. The application is supported by the foresiGHt Phase 3 trial, which demonstrated TransCon hGH's superiority in reducing trunk fat and increasing lean body mass, with a safe and well-tolerated profile.
Global Human Growth Hormones Market to Reach USD 10 Billion by 2030
Global Human Growth Hormones Market to reach USD 10 billion by 2030, driven by increasing prevalence of growth hormone deficiency, product approvals, and adoption of recombinant HGH. North America dominates the market, with key players including Novo Nordisk, Pfizer, and Eli Lilly. Market growth is fueled by advancements in biotechnology and rising demand for targeted therapies, despite challenges like stringent regulations and high treatment costs.
How to preserve muscle mass on weight-loss drugs like Wegovy
GLP-1 drugs like Wegovy and Zepbound can lead to significant weight loss but may also cause muscle loss. Researchers are concerned about the impact on muscle mass and function, which can affect health and mobility. Strategies to preserve muscle include a protein-rich diet, regular exercise, and potentially using drugs that prevent muscle loss.
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth
Lumos Pharma presented new Phase 2 OraGrowtH210 and OraGrowtH212 trial data at ESPE 2024, showing sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, with significant increases in Annualized Height Velocity (AHV) and IGF-1/IGFBP-3 levels. The data also demonstrated a correlation between LUM-201's pulsatile mechanism of action and growth, with plans to advance LUM-201 to a Phase 3 trial in moderate PGHD.
Groundbreaking research finds that Alzheimer's can be transmitted between people
Scientists found Alzheimer's transmission via contaminated cadaver-derived human growth hormone (c-hGH), used in 1,848 UK patients 1959-1985, withdrawn due to prion contamination. Five of eight treated individuals developed early-onset Alzheimer's, suggesting medical transmission of amyloid-beta protein.
FDA Rejects Camurus' Rare Hormonal Disorder Treatment Due to Manufacturing Problems
The FDA rejected Camurus' CAM2029 for acromegaly due to facility-related deficiencies, not clinical efficacy or safety. Camurus remains confident in CAM2029's potential and will work with the FDA to resolve the issue.
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to ...
Ascendis Pharma submits sBLA to FDA for TransCon hGH for adult GHD, based on Phase 3 foresiGHt trial results showing efficacy and safety. TransCon hGH aims to address unmet medical needs in GHD treatment.
The Importance of RWD in Rare Disease Research
Real-world data (RWD) is crucial in clinical research for cancer and rare diseases, used for retrospective and prospective studies, digital twins, synthetic control arms, surrogate endpoints, phenotyping, protocol design, patient identification, historical control arms, and long-term safety monitoring.
Daewoong Pharmaceutical secures IND approval for dissolvable microneedle growth hormone patch
Daewoong Pharmaceutical received IND approval for a phase 1 trial of its dissolvable microneedle patch for human growth hormone, aiming to compare its safety and pharmacokinetics with subcutaneous injections, and extend its use to pediatric patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath